OR WAIT null SECS
PAREXEL International Corporation announced that Bristol-Myers Squibb, a global biopharmaceutical company, has established a strategic partnership with PAREXEL to enable greater effectiveness in clinical development. PAREXEL will work collaboratively with Bristol-Myers Squibb to provide strategic, operational and capability support of its clinical development program. PAREXEL’s approach to strategic partnering focuses on assisting biopharmaceutical companies in reducing fixed costs, shortening development times, and speeding delivery of safe and effective treatments to market.
PAREXEL will help provide global execution of Bristol-Myers Squibb’s clinical studies to support its full development pipeline over the next three years. The agreement with PAREXEL will complement Bristol-Myers Squibb’s internal capabilities, helping to meet the increasing needs of its pipeline with high-quality clinical development services.
“This partnership will increase the operational capability of our clinical development organization, and support our position in productivity and innovation,” said Brian Daniels, Senior Vice President, Global Development, Bristol-Myers Squibb. “Working with PAREXEL, Bristol-Myers Squibb will enhance support for our pipeline and improve our ability to deliver innovative medicines to patients with serious diseases.”
“We look forward to a deeply collaborative relationship with Bristol-Myers Squibb to help provide innovative solutions for its growing pipeline, as well as to leverage our global capabilities and worldwide technology infrastructure to support the effectiveness of its clinical development programs,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International.